Bayer faces shake up after Lipobay withdrawnBMJ 2001; 323 doi: https://doi.org/10.1136/bmj.323.7317.828g (Published 13 October 2001) Cite this as: BMJ 2001;323:828
- Annette Tuffs
Two months after the withdrawal of cerivastatin (Lipobay) from the market because of associated deaths, the German manufacturer, Bayer, is still facing possible damaging consequences. In particular, it faces a collective legal claim by patients in the United States and is also having to restructure the firm.
In August Bayer decided to take cerivastatin off the market when several cases of deaths due to rhabdomyolysis came to light as a presumed consequence of high dose cerivastatin, especially in combination with another cholesterol lowering drug gemfibrozil (18 August, p 359).
There was a public …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial